← All trials
NCT00622843
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2002
- Primary completion
- Jul 1, 2013
- Completion date
- Jul 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 275
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Uniformed Services University of the Health SciencesLead sponsor
- United States ArmyCollaborator
- United States NavyOverall official - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Uniformed Services University of the Health SciencesReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.